The Efficacy of Double Doses of Oral Esomeprazole in Preventing Rebleeding for Patients With Bleeding Peptic Ulcers

PHASE4CompletedINTERVENTIONAL
Enrollment

474

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Peptic Ulcer Bleeding
Interventions
DRUG

esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)

"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients with Rockall score \>=6 are randomized into the double oral dose group and the regular oral dose group. Patients with Rockall score \<6 are assigned to the control group.~In the double oral dose group, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days. In the other two groups, patients receive 40 mg oral esomeprazole 40 mg once daily for 25 days."

Trial Locations (1)

704

National Cheng Kung University Hospital, Tainan City

All Listed Sponsors
collaborator

National Science and Technology Council, Taiwan

OTHER_GOV

lead

National Cheng-Kung University Hospital

OTHER

NCT01591083 - The Efficacy of Double Doses of Oral Esomeprazole in Preventing Rebleeding for Patients With Bleeding Peptic Ulcers | Biotech Hunter | Biotech Hunter